Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 3
1968 1
1969 3
1970 3
1971 3
1972 3
1973 7
1974 9
1975 24
1976 20
1977 19
1978 21
1979 23
1980 27
1981 23
1982 47
1983 58
1984 54
1985 75
1986 72
1987 94
1988 107
1989 81
1990 123
1991 112
1992 105
1993 151
1994 128
1995 127
1996 134
1997 117
1998 114
1999 120
2000 112
2001 137
2002 140
2003 138
2004 132
2005 141
2006 162
2007 158
2008 168
2009 187
2010 171
2011 187
2012 186
2013 213
2014 220
2015 220
2016 186
2017 214
2018 232
2019 252
2020 237
2021 216
2022 212
2023 181
2024 89

Text availability

Article attribute

Article type

Publication date

Search Results

5,929 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
However, the current standard of care--particularly for patients with relapsed disease--is often not sufficient to achieve durable remissions. A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT1 …
However, the current standard of care--particularly for patients with relapsed disease--is often not sufficient to achieve durable remission …
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up …
We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. …
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM. Johnson RJ, et al. Am J Kidney Dis. 2018 Jun;71(6):851-865. doi: 10.1053/j.ajkd.2017.12.009. Epub 2018 Feb 27. Am J Kidney Dis. 2018. PMID: 29496260 Free PMC article. Review.
Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. ...Although several small clinical trials suggest benefits of urate-loweri …
Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, c …
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA, Wesche H. Baeuerle PA, et al. Curr Opin Oncol. 2022 Sep 1;34(5):552-558. doi: 10.1097/CCO.0000000000000869. Epub 2022 Jul 28. Curr Opin Oncol. 2022. PMID: 35880455 Free PMC article. Review.
Many new TCEs in late-stage clinical development target various hematopoietic lineage markers like CD20, BCMA, or CD123. ...TCEs targeting peptide-MHC complexes will expand the target space for solid tumor therapy to intracellular targets. Likewise, early clinical …
Many new TCEs in late-stage clinical development target various hematopoietic lineage markers like CD20, BCMA, or CD123. ...TCEs targ …
Therapeutic cancer vaccines.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Schlom J, et al. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Adv Cancer Res. 2014. PMID: 24889529 Free PMC article. Review.
The wide spectrum of vaccine platforms and vaccine targets is reviewed along with the potential for development of vaccines to target cancer cell "stemness," the epithelial-to-mesenchymal transition (EMT) phenotype, and drug-resistant populations. Preclinical and recent clinic …
The wide spectrum of vaccine platforms and vaccine targets is reviewed along with the potential for development of vaccines to target cancer …
Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb.
Broderick C, Watson L, Armon MP. Broderick C, et al. Cochrane Database Syst Rev. 2021 Jan 19;1(1):CD002783. doi: 10.1002/14651858.CD002783.pub5. Cochrane Database Syst Rev. 2021. PMID: 33464575 Free PMC article.
We pooled data using a fixed-effect model, unless we identified heterogeneity, in which case we used a random-effects model. The primary outcomes of interest were clot lysis, bleeding and post thrombotic syndrome. ...Two studies reported on clot lysis at late …
We pooled data using a fixed-effect model, unless we identified heterogeneity, in which case we used a random-effects model. The prim …
Combination immunotherapy strategies for glioblastoma.
Chan HY, Choi J, Jackson C, Lim M. Chan HY, et al. J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611705 Review.
Recent preclinical and clinical studies have explored combining ICB with several other therapies including additional ICB against alternative checkpoint molecules, activation of costimulatory checkpoint molecules such as 4-1BB, radiation-induced tumor cell lysis and …
Recent preclinical and clinical studies have explored combining ICB with several other therapies including additional ICB against alt …
Eculizumab.
Davis J. Davis J. Am J Health Syst Pharm. 2008 Sep 1;65(17):1609-15. doi: 10.2146/ajhp080043. Am J Health Syst Pharm. 2008. PMID: 18714106
PURPOSE: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed. ...It binds specifically to complement protein C5 and inhibits cleavage to C5a and C5b, resulting in t …
PURPOSE: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and admin …
Viruses as nanomedicine for cancer.
Badrinath N, Heo J, Yoo SY. Badrinath N, et al. Int J Nanomedicine. 2016 Sep 21;11:4835-4847. doi: 10.2147/IJN.S116447. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27703350 Free PMC article. Review.
Armed with antitumor cellular molecules, antibodies, and/or in combination with anticancer drugs, OVs can accelerate the lysis of cancer cells. Among the OVs, vaccinia virus has been the focus of preclinical and clinical research because of its many favorable proper …
Armed with antitumor cellular molecules, antibodies, and/or in combination with anticancer drugs, OVs can accelerate the lysis of can …
Ravulizumab: First Global Approval.
McKeage K. McKeage K. Drugs. 2019 Feb;79(3):347-352. doi: 10.1007/s40265-019-01068-2. Drugs. 2019. PMID: 30767127 Review.
Like the first-generation C5 inhibitor, eculizumab, ravulizumab binds specifically and with high affinity to the complement protein C5, thereby preventing formation of the terminal complement complex C5b-9, which mediates cell lysis. In December 2018, intravenous ravulizum …
Like the first-generation C5 inhibitor, eculizumab, ravulizumab binds specifically and with high affinity to the complement protein C5, ther …
5,929 results